PVLA

Palvella TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$185.00

+76.7% vs current

Most likely

Base case

40%

Probability

Target price

$125.00

+19.4% vs current

B-

Bear case

30%

Probability

Target price

$70.00

-33.1% vs current

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Sentiment is constructive on the back of SELVA success and the larger cash position, but the updated deterministic prior is notably cooler than the earlier baseline, with lower evidence quality and sparse near-term catalysts. That argues for a cautious monitoring stance rather than an aggressive bullish call.

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystPhase 2 angiokeratoma study initiation expected in Q2 2026High impact

Management said it received FDA written feedback and now expects the Phase 2 study in clinically significant angiokeratomas to start in Q2 2026, earlier than prior 2H 2026 guidance; hitting that timing would show the QTORIN platform is extending beyond the lead indication [#PR-2026-03-31].

2026-10-15eventQTORIN rapamycin NDA submission for microcystic LMs in 2H 2026High impact

After positive Phase 3 SELVA topline results, Palvella said it plans to submit an NDA in the second half of 2026 for microcystic lymphatic malformations; NDA timing is the clearest value-defining checkpoint from here [#PR-2026-02-24][#PR-2026-03-31].

2027-06-30catalystPotential first U.S. approval window in 1H 2027High impact

Company materials frame a potential first-half 2027 U.S. approval for QTORIN rapamycin if the filing and review proceed well; the setup is helped by positive Phase 3 data and pro forma cash of about $274 million after the February 2026 financing, but this remains a single-asset regulatory path with execution risk [#PR-2026-02-24][#PR-2026-03-31][#10-K-2026-03-31].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology